News

CLINUVEL
Posted by CLINUVEL
September 19, 2022

Strategic Update V

CLINUVEL today announced its fifth Strategic Update, focused on the evolution and...

Read More
CLINUVEL
Posted by CLINUVEL
September 13, 2022

H.C. Wainwright 24th Annual Global Investment Conference

CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...

Read More
CLINUVEL
Posted by CLINUVEL
September 8, 2022

CLINUVEL confirms AGM date

CLINUVEL confirms the date for the Company’s 2022 Annual General Meeting.

Read More
Lachlan Hay
Posted by Lachlan Hay
September 5, 2022

CLINUVEL submits SCENESSE® label expansion for adolescent EPP patients

European regulatory submission follows clinical support for SCENESSE® treatment in EPP patients...

Read More
CLINUVEL
Posted by CLINUVEL
September 2, 2022

CLINUVEL Kommuniqué IV

Seit dem letzten News Communiqué vom 23. Juni hat CLINUVEL die Entwicklung...

Read More
CLINUVEL
Posted by CLINUVEL
August 31, 2022

CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2022

CLINUVEL PHARMACEUTICALS LTD hosted an investor webinar on the financial results for...

Read More
CLINUVEL
Posted by CLINUVEL
August 30, 2022

Appendix 4G

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4G

Read More
CLINUVEL
Posted by CLINUVEL
August 30, 2022

Revenue Growth Drives CLINUVEL's Sixth Consecutive Annual Profit

CLINUVEL today announced its sixth consecutive annual net profit, driven by revenues...

Read More
CLINUVEL
Posted by CLINUVEL
August 30, 2022

Dividend/Distribution – CUV

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4E and Annual Report

Read More
CLINUVEL
Posted by CLINUVEL
August 30, 2022

Appendix 4E & Annual Report

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4E and Annual Report

Read More